Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome

Learn more about:
Related Clinical Trial
Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma RB Liquid Biopsy Biorepository Topotecan and Melphalan for Retinoblastoma Effect of Anesthetic Drugs on Neurocognitive Function in Children With Retinoblastoma Requiring Multiple Anesthetic Exposure – Preliminary Study Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome Nitroglycerin for Intra-arterial Chemotherapy in Pediatric Retinoblastoma. Autonomic Reflexes During Intra-arterial Chemotherapy for Retinoblastoma Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma Photodynamic Therapy With Visudyne for Human Retinoblastoma: A Preliminary Study Topotecan Episcleral Plaque for Treatment of Retinoblastoma G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment PCI Imaging System in Pediatric Ophthalmology Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma Determining Whether Multiple Anesthesia Exposures Affect Cognitive Function for Retinoblastoma Patients Conservative Treatments of Retinoblastoma Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma Intra-arterial Chemotherapy for Advanced Intraocular Retinoblastoma Photoscreening for Retinoblastoma RCT of Ballon Technique VS Selective Ophthalmic Artery Infusion For the Retinoblastoma Patients Studying Health Outcomes After Treatment in Patients With Retinoblastoma Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers A Study of the Effectiveness of a Local Injection of Chemotherapy for Retinoblastoma Intra-arterial Chemotherapy for Retinoblastoma Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in Advanced Intraocular Stage Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma Phase I Trial of Periocular Topotecan in Retinoblastoma Episcleral Topotecan for Treatment of Group D Retinoblastoma Can Pretreatment MRI be Used to Predict Intra-arterial Chemotherapy Response in Retinoblastoma? CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma Chemotherapy With or Without Radiation Therapy or Observation in Treating Young Patients With Advanced Retinoblastoma Who Have Undergone Surgery to Remove the Eye Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With Retinoblastoma Intravitreal Carboplatin for the Treatment of Participants With Recurrent or Refractory Intraocular Retinoblastoma Superselective Intra-arterial Chemotherapy Treatment for Retinoblastoma- 5 Year Results From Turkey Intra-arterial Chemotherapy(Chemosurgery) for Retinoblastoma Adjuvant Chemotherapy for High-risk Retinoblastoma After Enucleation Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma Chemotherapy in Treating Patients With Retinoblastoma New Strategies to Detect Cancers in Carriers of Mutations in RB1 Pilot Study of Topotecan/Vincristine With Subconjunctival Carboplatin for Patients With Bilateral Retinoblastoma Carboplatin Plus Vincristine in Treating Children With Retinoblastoma Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma Proton Beam Radiation Therapy for Intraocular and Periocular Retinoblastoma Quality of Life in Children Cured of Retinoblastoma Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009) Cardio-respiratory Events During Ophthalmic Artery Chemotherapy for Retinoblastoma Under a Deep Anesthesia Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma SPT Screening in Irradiated Hereditary Retinoblastoma Survivors Attention to Retinoblastoma Diagnosed in the Trauma Setting Carboplatin Periocular Injection for Retinoblastoma Morphological Analysis of the Pineal Gland in Pediatric Retinoblastoma Patients Using Magnetic Resonance Imaging Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From Guatemala Research on the Environment and Children’s Health: Retinoblastoma Intravitreal Injections of Melphalan for Retinoblastoma Efficacy Study of Lucentis in the Treatment of Retinoblastoma Feasibility of Generating Pluripotent Stem Cells From Patients With Familial Retinoblastoma A Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma Retinoblastoma Survivor Study: Assessment of General Health and Quality of Life Retinoblastoma Biomarker Study Cancer Biology of Retinoblastoma Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma Intra-arterial Chemotherapy for Children With Retinoblastoma Molecular Analysis of Retinoblastoma

Brief Title

Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome

Official Title

Ocular Conservative Treatment for Retinoblastoma: Efficacy of the New Management Strategies and Visual Outcome - RETINO 2018

Brief Summary

      This protocol includes 2 independent studies. Both studies are multicenter studies,
      evaluating different therapeutic approaches in two different populations of patients:

        -  Study 1, a randomized phase-II study evaluating the efficacy of Intra-Arterial
           Chemotherapy (IAC) with melphalan and topotecan versus melphalan alone, both in
           association with ophthalmologic treatments.

        -  Study 2, a minimally invasive interventional study evaluating the results on visual
           function following reference treatment with intravenous (IV) chemotherapy in association
           with ophthalmologic treatments.

Detailed Description

      Primary objective of the studies:

        -  Study 1: To evaluate the efficacy of IAC in term of local control of the disease in
           patients eligible for IAC (randomized phase II study);

        -  Study 2: To assess the visual function, based on World Health Organization (WHO)
           criteria, in patients eligible for other conservative treatments (IV chemotherapy in
           association with local ophthalmologic treatments; this is a minimally invasive
           interventional study).

Study Phase

Phase 2/Phase 3

Study Type


Primary Outcome

Study 1: Rate of eye preservation

Secondary Outcome

 Ocular toxicity




Melphalan or Melphalan + Topotecan

Study Arms / Comparison Groups

 Study 1: Melphalan or Melphalan + Topotecan
Description:  Randomized phase-II study evaluating the efficacy of Intra-Arterial Chemotherapy (IAC) with melphalan and topotecan versus melphalan alone, both in association with ophthalmologic treatments.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

February 11, 2021

Completion Date

January 20, 2036

Primary Completion Date

January 20, 2035

Eligibility Criteria

        Inclusion Criteria:

        Overall study inclusion criteria:

          1. Newly diagnosed retinoblastoma (RB).

          2. Retinoblastoma with at least one eye eligible for conservative management.

          3. Patients likely to be compliant with the study requirements and visits, including late

          4. Patients not previously treated with chemotherapy or radiotherapy for this or any
             other cancer.

          5. Patients with no contraindication to the proposed treatments.

          6. Informed consent signed by parents or legal representative.

          7. French Social Security System coverage.

        Study 1 inclusion criteria:

        8.1. Children aged from 6 months to 6 years. 9. Retinoblastoma in at least one eye, deemed
        manageable with IAC in one side and without IV chemotherapy:

          1. Unilateral Retinoblastoma classified as group B, C (if vitreous seeds < 3 mm), D or E
             with no invasion of the anterior segment, and without massive tumor of more than 2/3
             of the eye, eligible for conservative management, or

          2. Bilateral Retinoblastoma but with very unbalanced lesions between the two eyes: one
             eye group D or E without invasion of the anterior segment or massive tumor of more
             than 2/3 of the eye, eligible for IAC, and the other eye eligible for local treatment
             only (without IAC).

        Study 2 inclusion criteria:

        8.2. Retinoblastoma eligible for conservative management although not manageable with IAC:

          1. Unilateral Retinoblastoma in children below 6 months of age, classified as Group A, B,
             C or D, with or without vitreous seeding, compatible with conservative management, or

          2. Bilateral Retinoblastoma classified as group A, B, C D, or E without invasion of the
             anterior segment, and/or massive tumors of more than 2/3 of the eye and eligible for
             conservative management.

        Exclusion Criteria:

        Overall study non-inclusion criteria:

          1. RB not eligible for conservative management :

               1. Extra-ocular extension of the disease, or

               2. Group E eyes with invasion of the anterior segment, and/or massive tumors of more
                  than 2/3 of the eye.

          2. Patient older than 6 years of age.

          3. Patients with another associated disease contra indicating systemic chemotherapy.

          4. Previously treated retinoblastoma by chemotherapy.

          5. Patients already treated for another malignant disease.

          6. Patient with any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule.

          7. Patients whose parents have not accepted the treatment regimen after explanation of

          8. Contraindication to study drug mentioned in SmPC (Summary of Products Characteristics)
             of the study drugs.

          9. Inclusion in another experimental anti-cancer drug therapy.

             Study 1 non-inclusion criteria:

         10. Any contraindication or concomitant disease that would preclude the Study 1 treatment
             procedure and could delay treatment.

        These patients should be eligible for Study 2.




6 Months - 6 Years

Accepts Healthy Volunteers



, +33(0)144324163, [email protected]

Location Countries


Location Countries


Administrative Informations



Organization ID

IC 2019-05

Responsible Party


Study Sponsor

Institut Curie


 Fondation Rothschild Paris

Study Sponsor

, , 

Verification Date

December 2020